Patents by Inventor Robert M. Jones

Robert M. Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12122113
    Abstract: A sipe forming assembly is provided. The sipe forming assembly includes a plunge cutting assembly, a leading roller assembly positioned upstream of the plunge cutting assembly, and a trailing roller assembly positioned downstream of the plunge cutting assembly. The plunge cutting assembly includes a blade and a linear actuator configured to actuate the blade to cut a sipe in a tire tread. The leading roller assembly includes a first leading roller and a second leading roller positionable relative to the first leading roller. The second leading roller and the first leading roller are configured to cooperate to clamp the tire tread between the first leading roller and the second leading roller. The trailing roller assembly includes a first trailing roller and a second trailing roller configured to cooperate to clamp the tire tread between the first trailing roller and the second trailing roller.
    Type: Grant
    Filed: February 2, 2022
    Date of Patent: October 22, 2024
    Assignee: Bridgestone Bandag, LLC
    Inventors: Troy A. Kost, Jim L. Jones, Robert G. Otting, Logan M. Koepke
  • Publication number: 20240336574
    Abstract: The invention provides methyl-substituted pyridine and pyridazine compounds, derivatives thereof, and methods of their use. The compounds are useful as pharmacological agents to treat a variety of conditions, including various pain states, itch, and cough.
    Type: Application
    Filed: March 10, 2022
    Publication date: October 10, 2024
    Inventors: Robert M. Jones, Ashok Bajji, Nathaniel Julius Thomas Monck, Suzanne J. O'Connor, William H. Gardiner, Robert James Townsend, Andreina Pacheco Pita, Michael Brunavs, Abdul Kadar Shaikh, Jonathan Paul Shine, Ian James Wigginton, Jonathan Philip Richards, Marco Michele Mastandrea, Adam James Davenport, Bryan Moyer, Michael Poslusney, James Barrow, Richard Edmund Rathmell
  • Patent number: 12109219
    Abstract: Provided are certain methods useful in the treatment of cancer comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor;
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: October 8, 2024
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Jayant Thatte, Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Jae-Kyu Jung, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter, Sonja Strah-Pleynet, Lars Thoresen, Yifeng Xiong, Dawei Yue, Xiuwen Zhu
  • Patent number: 12079115
    Abstract: A system including a development environment data store configured to store development environment data associated with development computer code and a production environment data store configured to store production environment data pertaining to one or more electronic services. The system includes a scenario builder computer is configured to identify one or more scenario parameters relevant to the development computer code, the one or more scenario parameters comprising less than a full set of available scenario parameters and provides the one or more scenario parameters to a scrubber computer.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: September 3, 2024
    Assignee: United Services Automobile Association (USAA)
    Inventors: Robert Lee Black, Timothy Blair Chalmers, Sumita T. Jonak, David M. Jones, Jr., Gideon Bowie Luck, Ana Rosa Maldonado, Oscar Roberto Tijerina
  • Patent number: 12045437
    Abstract: An example process includes: while displaying a user interface different from a digital assistant user interface, receiving a user input; in accordance with a determination that the user input satisfies a criterion for initiating a digital assistant: displaying, over the user interface, the digital assistant user interface, the digital assistant user interface including: a digital assistant indicator displayed at a first portion of the display; and a response affordance displayed at a second portion of the display, where: a portion of the user interface remains visible at a third portion of the display; and the third portion is between the first portion and the second portion.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: July 23, 2024
    Assignee: Apple Inc.
    Inventors: Neal Ellis, Oluwatomiwa B. Alabi, Robert Burton, Richard R. Dellinger, Thomas R. Fazio, Craig M. Federighi, Rebecca P. Fish, Nikrouz Ghotbi, James N. Jones, Ieyuki Kawashima, Stephen O. Lemay, Pedro Mari, Aaron Musengo, James E. Palmer, Patchaya Beam Seilaudom, Andrea Valentina Simes, Tyler McClay Smith, Trungtin Tran, Robert A. Walker, II
  • Patent number: 11897873
    Abstract: Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: wherein X, Y, R1, R2, R4, R5, R6, R7, R8 and R11 are as defined herein.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: February 13, 2024
    Assignees: BLACKTHORN THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Edward Roberts, Miguel A. Guerrero, Mariangela Urbano, Hugh Rosen, Robert M. Jones, Candace Mae Laxamana, Xianrui Zhao, Eric Douglas Turtle
  • Patent number: 11858943
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R1, R1b, R1c, R2 and X are as defined herein.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: January 2, 2024
    Assignee: NEUMORA THERAPEUTICS, INC.
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, David Hardick, Chris Knight, Jason Tierney
  • Patent number: 11771695
    Abstract: Provided are certain methods useful in the treatment of pain comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor;
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: October 3, 2023
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Jayant Thatte, Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Jae-Kyu Jung, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter, Sonja Strah-Pleynet, Lars Thoresen, Yifeng Xiong, Dawei Yue, Xiuwen Zhu
  • Patent number: 11746091
    Abstract: The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: September 5, 2023
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Sangdon Han, Lars Thoresen, Jae-Kyu Jung, Sonja Strah-Pleynet, Xiuwen Zhu, Yifeng Xiong, Dawei Yue
  • Publication number: 20230257349
    Abstract: The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.
    Type: Application
    Filed: August 11, 2022
    Publication date: August 17, 2023
    Inventors: Robert M. Jones, Daniel J. Buzard, Sangdon Han, Sun Hee Kim, Juerg Lehmann, Brett Ullman, Jeanne V. Moody, Xiuwen Zhu, Scott Stirn
  • Publication number: 20230149353
    Abstract: The present invention relates to, inter alia, methods of treatment and combinations of (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) useful for the treatment of primary biliary cholangitis (PBC). In some embodiments, the methods further comprise administering Compound 1, or a pharmaceutically salt, solvate, or hydrate thereof, in combination with a compound selected from the group consisting of: an antihistamine (diphenhydramine), cholestyramine (questran, prevalite), rifampin, an opioid antagonist (naloxone), pilocarpine (isopto carpine, salagen), cevimeline (evox-ac), calcium and/or vitamin D supplement, and vitamin A, D, E and/or K supplement. Other embodiments, relate to titration packages for enabling compliance with a regimen of changing dosage of a medication over a period of time for the treatment of primary biliary cholangitis (PBC).
    Type: Application
    Filed: November 18, 2022
    Publication date: May 18, 2023
    Inventors: Cheryl Geraldine Lassen, Robert M. Jones, Que Liu, Ronald J. Christopher
  • Publication number: 20230093235
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R1, R1b, R1c, R2 and X are as defined herein.
    Type: Application
    Filed: October 13, 2021
    Publication date: March 23, 2023
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, David Hardick, Chris Knight, Jason Tierney
  • Patent number: 11560369
    Abstract: The present invention relates to crystalline forms of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor and are therefore useful in the treatment of CB2 receptor-mediated disorders, for example, osteoarthritis; pain; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation for example; atherosclerosis; undesired immune cell activity, and inflammation associated with a disorder selected from: osteoarthritis, anaphylaxis, Behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus; age-related macular degeneration; cough;
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: January 24, 2023
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter
  • Publication number: 20220306586
    Abstract: The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor.
    Type: Application
    Filed: November 8, 2021
    Publication date: September 29, 2022
    Inventors: Robert M. Jones, Sangdon Han, Lars Thoresen, Jae-Kyu Jung, Sonja Strah-Pleynet, Xiuwen Zhu, Yifeng Xiong, Dawei Yue
  • Publication number: 20220241274
    Abstract: Provided are certain methods useful in the treatment of pain comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor;
    Type: Application
    Filed: September 17, 2021
    Publication date: August 4, 2022
    Inventors: Jayant Thatte, Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Jae-Kyu Jung, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter, Sonja Strah-Pleynet, Lars Thoresen, Yifeng Xiong, Dawei Yue, Xiuwen Zhu
  • Publication number: 20220162202
    Abstract: Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof. wherein X, Y, R1, R2, R4, R5, R6, R7, R8 and R11 are as defined herein.
    Type: Application
    Filed: July 30, 2021
    Publication date: May 26, 2022
    Inventors: Edward Roberts, Miguel A. Guerrero, Mariangela Urbano, Hugh Rosen, Robert M. Jones, Candace Mae Laxamana, Xianrui Zhao, Eric Douglas Turtle
  • Patent number: 11235874
    Abstract: Systems and methods for the automated aerial application of chemicals onto agricultural areas. Unmanned aerial vehicles (UAVs) are configured to selectively attach to modular sprayer payloads, each payload having a payload reservoir, a spray nozzle, a pump, and a battery. A ground station having landing pads for the UAVs is configured to coordinate and automatically fill at least one payload reservoir from a material tank and provide the payload to a given UAV. A control subsystem can determine a mission plan and command the UAV to selectively deliver the contents of the payload reservoir to at least a portion of one or more agricultural areas.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: February 1, 2022
    Assignee: Greensight Agronomics, Inc.
    Inventors: Robert M. Jones, James R. Peverill, Andrew D. Delollis
  • Patent number: 11214548
    Abstract: The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: January 4, 2022
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Sangdon Han, Lars Thoresen, Jae-Kyu Jung, Sonja Strah-Pleynet, Xiuwen Zhu, Yifeng Xiong, Dawei Yue
  • Publication number: 20210380560
    Abstract: The present invention relates to crystalline forms of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor and are therefore useful in the treatment of CB2 receptor-mediated disorders, for example, osteoarthritis; pain; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation for example; atherosclerosis; undesired immune cell activity, and inflammation associated with a disorder selected from: osteoarthritis, anaphylaxis, Behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus; age-related macular degeneration; cough;
    Type: Application
    Filed: March 16, 2021
    Publication date: December 9, 2021
    Inventors: Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter
  • Patent number: 11186577
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R1, R1b, R1c, R2 and X are as defined herein.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: November 30, 2021
    Assignee: BLACKTHORN THERAPEUTICS, INC.
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, David Hardick, Chris Knight, Jason Tierney